|
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) Valation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) Bundle
Découvrez le véritable potentiel de Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ) avec notre calculatrice avancée DCF! Ajustez les hypothèses critiques, explorez divers scénarios et examinez comment les fluctuations affectent l'évaluation de Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ) - le tout dans un modèle Excel complet.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,531.5 | 1,895.8 | 2,429.1 | 2,676.2 | 2,610.6 | 2,680.6 | 2,752.6 | 2,826.5 | 2,902.3 | 2,980.2 |
| Revenue Growth, % | 0 | -25.11 | 28.13 | 10.17 | -2.45 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 |
| EBITDA | 525.4 | -207.0 | 479.3 | 542.8 | 451.7 | 360.0 | 369.7 | 379.6 | 389.8 | 400.3 |
| EBITDA, % | 20.75 | -10.92 | 19.73 | 20.28 | 17.3 | 13.43 | 13.43 | 13.43 | 13.43 | 13.43 |
| Depreciation | 98.9 | 97.5 | 95.5 | 99.9 | 121.2 | 114.5 | 117.6 | 120.7 | 124.0 | 127.3 |
| Depreciation, % | 3.91 | 5.14 | 3.93 | 3.73 | 4.64 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 |
| EBIT | 426.5 | -304.6 | 383.8 | 442.9 | 330.6 | 245.5 | 252.1 | 258.9 | 265.8 | 273.0 |
| EBIT, % | 16.85 | -16.06 | 15.8 | 16.55 | 12.66 | 9.16 | 9.16 | 9.16 | 9.16 | 9.16 |
| Total Cash | 819.9 | 1,630.3 | 1,256.3 | 1,268.4 | 1,935.1 | 1,563.4 | 1,605.4 | 1,648.5 | 1,692.8 | 1,738.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,217.2 | 955.6 | 792.5 | 1,203.6 | 1,027.8 | 1,155.1 | 1,186.1 | 1,217.9 | 1,250.6 | 1,284.2 |
| Account Receivables, % | 48.08 | 50.4 | 32.62 | 44.97 | 39.37 | 43.09 | 43.09 | 43.09 | 43.09 | 43.09 |
| Inventories | 373.9 | 403.8 | 452.2 | 481.1 | 520.4 | 496.4 | 509.8 | 523.4 | 537.5 | 551.9 |
| Inventories, % | 14.77 | 21.3 | 18.62 | 17.98 | 19.93 | 18.52 | 18.52 | 18.52 | 18.52 | 18.52 |
| Accounts Payable | 88.9 | 88.8 | 106.7 | 126.3 | 93.8 | 112.0 | 115.1 | 118.1 | 121.3 | 124.6 |
| Accounts Payable, % | 3.51 | 4.68 | 4.39 | 4.72 | 3.59 | 4.18 | 4.18 | 4.18 | 4.18 | 4.18 |
| Capital Expenditure | -128.3 | -154.4 | -213.8 | -268.0 | -363.1 | -246.3 | -252.9 | -259.7 | -266.6 | -273.8 |
| Capital Expenditure, % | -5.07 | -8.15 | -8.8 | -10.01 | -13.91 | -9.19 | -9.19 | -9.19 | -9.19 | -9.19 |
| Tax Rate, % | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 |
| EBITAT | 357.7 | -383.2 | 344.3 | 387.3 | 306.8 | 222.9 | 228.8 | 235.0 | 241.3 | 247.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,174.0 | -208.5 | 358.7 | -201.2 | 168.8 | 6.0 | 52.2 | 53.6 | 55.0 | 56.5 |
| WACC, % | 7.38 | 7.46 | 7.41 | 7.4 | 7.43 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 174.9 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 58 | |||||||||
| Terminal Value | 1,318 | |||||||||
| Present Terminal Value | 921 | |||||||||
| Enterprise Value | 1,096 | |||||||||
| Net Debt | -527 | |||||||||
| Equity Value | 1,624 | |||||||||
| Diluted Shares Outstanding, MM | 823 | |||||||||
| Equity Value Per Share | 1.97 |
What You Will Receive
- Customizable Excel Template: A tailored Excel-based DCF Calculator featuring pre-populated financial data for Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ).
- Accurate Market Data: Historical figures and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify assumptions related to revenue growth, EBITDA %, and WACC as needed.
- Instant Calculations: Immediately observe how your inputs influence the valuation of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ).
- Professional Resource: Designed specifically for investors, CFOs, consultants, and financial analysts.
- User-Centric Layout: Organized for simplicity and usability, complete with step-by-step guidance.
Key Features
- Accurate Financial Data for Guangdong Zhongsheng Pharmaceutical (002317SZ): Gain access to reliable historical information and forecasts.
- Customizable Financial Assumptions: Adjust highlighted values including WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatically refresh DCF, Net Present Value (NPV), and cash flow analyses.
- User-Friendly Dashboard: Intuitive charts and summaries to easily interpret your valuation results.
- Designed for All Skill Levels: A straightforward and accessible layout tailored for investors, CFOs, and consultants.
How It Works
- Step 1: Download the Excel file.
- Step 2: Examine Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s pre-filled financial information and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify the assumptions.
- Step 5: Evaluate the results and leverage them for your investment strategies.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and consultants.
- Comprehensive Data: Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (002317SZ) historical and projected financials preloaded for precision.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to help you navigate through the calculations.
Who Should Use This Product?
- Investors: Evaluate the valuation of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ) before making trading decisions.
- CFOs and Financial Analysts: Enhance valuation workflows and validate financial forecasts.
- Startup Founders: Gain insights into the valuation methods used for established companies like Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317SZ).
- Consultants: Create comprehensive valuation reports for your clients.
- Students and Educators: Utilize real data to explore and teach valuation methodologies.
Contents of the Template
- Preloaded 002317SZ Data: Historical and forecasted financial metrics, encompassing revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade spreadsheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for customizing revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financials for in-depth analysis.
- Key Ratios: Metrics on profitability, leverage, and efficiency for performance assessment.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.